Ticker Details
Exelixis, Inc. Common Stock Exelixis Inc is a biotechnology company. It is involved in discovery, development, and commercialization of new medicines for people with cancer. The Cabometyx product generates maximum revenue for the company.
IPO Date:	May 1, 2000
Sector:	Healthcare
Industry:	Biotech
Market Cap:	$11.79B
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$0.26 | 2.17%
Avg Daily Range (30 D):	$0.53 | 1.25%
Avg Daily Range (90 D):	$0.61 | 1.40%

Institutional Daily Volume
Avg Daily Volume:	2.07M
Avg Daily Volume (30 D):	2.13M
Avg Daily Volume (90 D):	2.07M

Trade Size
Avg Trade Size (Sh.):	154
Avg Trade Size (Sh.) (30 D):	59
Avg Trade Size (Sh.) (90 D):	61

Institutional Trades
Total Institutional Trades:	12,647
Avg Institutional Trade:	$3.06M
Avg Institutional Trade (30 D):	$6.68M
Avg Institutional Trade (90 D):	$5.9M
Avg Institutional Trade Volume:	.16M
Avg Institutional Trades (Per Day):	3

Market Closing Trades
Avg Closing Trade:	$7.46M
Avg Closing Trade (30 D):	$25.7M
Avg Closing Trade (90 D):	$21.73M
Avg Closing Volume:	336.25K

News

Mar 18, 2026 @ 12:30 PM The Best Healthcare Stocks to Buy With $50 Right N... Source: Prosper Junior Bakiny

Feb 28, 2026 @ 9:37 AM 3 Reasons Exelixis Stock Could Deliver Marketâ€... Source: James Halley

Jan 15, 2026 @ 11:44 AM InSilico Lands Drug Discovery Deal After Hong Kong... Source: Bamboo Works

Jan 8, 2026 @ 10:15 AM 2 Healthcare Stocks to Buy for 2026 and Beyond Source: Prosper Junior Bakiny

Dec 2, 2025 @ 1:06 AM 2 Under-the-Radar Stocks to Buy Heading Into 2026 Source: Prosper Junior Bakiny

Financials
	TTM	Q3 2026	Q2 2026
Basic EPS		$.72	$.68
Diluted EPS		$.69	$.65
Revenue		$597.76M	$568.26M
Gross Profit		$579.18M	$548.79M
Net Income / Loss		$193.58M	$184.85M
Operating Income / Loss		$236.54M	$213.58M
Cost of Revenue		$18.57M	$19.47M
Net Cash Flow		$211.87M	$-19.32M
PE Ratio